AI Agents for Precedent Transaction Analysis

For the Kenvue deal, please send over the below draft figures for pre-deal target multiples for FY24. Utilize potential median deal value Return to me a message with: Deal value/EBITDA, Deal value/EBIT, and Deal value/OpFCF. Round all values to one decimal place.

Update the base-case DCF model of KVUE with U.S. total equity risk premium of 4.33%, the risk free rate with the 5-Year Treasury rate and the KVUE Close share price on 2025-12-15. Let's measure the impact of an increase in tax rate by 4 percentage points (apply to 2025E-2029E and the WACC tax shield) and the decrease in terminal growth rate by 0.25 percentage points. Reply back to me, giving the updated enterprise value, equity value and implied share price, rounded to two decimal places. Express enterprise value and equity value in millions.

Reply back to me with the following values: - Implied share price. - Enterprise value - % weight of PV of terminal value in the total new EV. To get to the right answer, update the WACC calculation in the DCF model: replace the risk-free rate with the 5-year Treasury rate as of Dec 15, 2025, and use 4.33% as the total equity risk premium for the United States of America. Then, apply the following changes for the forecast years 2025E-2029E: reduce the operating margin by 2 percentage points in each forecast year, set the yearly revenue growth rate to 1.22% in each forecast year, and set CAPEX equal to D&A in each forecast year. Keep everything else the same. When you reply, round the values to two decimal places, express in $millions.

Please calculate the implied premium / discount of the offer price as proposed to the client relative to the following KVUE share prices, using the values up to 12/08/2025: - Closing price on the final day - 52 week high closing price - 52 week low closing price - last 30 trading day VWAP - last 90 trading day VWAP Report percentages to one decimal place. Use unadjusted prices and calculate VWAP based on the daily closing prices. All dates are in MM/DD/YYYY format. Reply back with your answer here.

In a hypothetical acquisition of Kenvue by Kimberly Clark (merger), at what Kimberly Clark share price would accretion for Pro Forma 2025 EPS for the combined company (Kenvue and Kimberly Clark) would be exactly 0.00%? Assume KVUE' share price before applying a premium is the average closing daily price between 1/1/2025 and 06/30/2025. All other assumptions in the base merger model should not be changed. Return your result as a message, give it in dollars with 2 decimal places.

Take the average close price for KVUE for the week of 12/15/2025 to 12/19/2025, apply a 10% premium, and input that figure in the DCF model. Re-calculate both the 1) cost of equity and 2) after-tax cost of debt. Output your answer as a reply here, rounded to two decimal points.

Calculate the NPV from the 12-year cash flow on renewable enablement benefits, considering the following assumptions: - The steady-state annual benefits from renewable enablement mentioned in the business case represent the annual renewables revenue for year 1, which then grows at a rate of 10% during each of the next 11 years. - The OPEX is provided in the attached slide deck. - Assume an 8% annual discount rate, and no discount in the 1st year. State the final NPV in billions with two decimal places here as a message here

I need to compare our results from the autonomous vehicle survey and the survey questionnaire against the attached 2025 launch targets. For these three metrics, calculate the percentage points gap between what we measured and our target: 1) What percentage of European respondents expect AVs to go mainstream within the next 5 years (inclusive of 5 years), compared to our Europe target? 2) What share of total global respondents would pay over $100 per month for AV subscriptions versus our $100+ tier target? 3) What is our high-trust percentage (scores of 4-5) compared to the consumer trust target? Please provide each answer as a reply to me in here, rounded to whole numbers.

Using the latest pricing version, the revenue data by segment, and the discount approval logs, determine the average discount percentage for each of the Business and Growth tiers separately (use the midpoint of the Company Size range as the user count). Then, calculate the %variance of each tier's discount relative to its average policy threshold. Provide the discount for each tier (rounded to the nearest 0.01%) as well as the variance from policy threshold (rounded to the nearest 0.01%) directly here as a reply.

For 2024 Won/Upsold deals with NCV ≥ 50k, determine the policy-friction risk per deal as NCV × Discount × tier multiplier × tier PFI, where tier PFI is the benchmark mix-weighted sum of Software Customer User Satisfaction Survey Results. After you rank the regions by the total policy-friction risk, please give me the top 3 regions and their respective total policy friction risk (in $M, rounded to three decimal places) in any order. Refer to the following three files: 1) Deal Transactions sheet, 2) the Customer User Satisfaction Survey Results chart in the software pricing trends doc, and 3) the attached policy mix and multiplier charts. Give me your answers as a reply right here.

Use the churn and WinLoss data, and assume the following: - Competitor Loss Ratio = (Total Contract Value of Lost deals/Total Contract Value of all deals) - If competitor-lost deal value exceeds the retained renewal ARR for that tier: Increase the churned ARR for that tier by 15% - If retained renewal ARR exceeds competitor-lost deal value: Reduce the competitor-lost contract value by 50% - Severity Score = Adjusted Competitor Pressure + (Adjusted Churn Rate x (Adjusted Competitor Lost Value/ Original ARR)) - Competitive Exposure Multiplier = Highest Severity Score ÷ Adjusted Competitor Pressure of that tier - Scenario Sensitivity Factor = Highest Severity Score * (Adjusted Competitor Pressure + Adjusted Churn Rate) Answer the following questions: 1. Which pricing tier has the highest severity score? 2. What is the highest severity score? 3. For the tier identified with the highest severity score, what is the single most frequent competitor appearing in lost deals? (If multiple competitors, return the alphabetically first) 4. For the tier identified with the highest severity score, calculate the Severity Score to Adjusted Churn Rate ratio 5. For the tier identified with the highest severity score, calculate the Competitive Exposure Multiplier? 6. For the tier identified with the highest severity score, calculate the Scenario Sensitivity Factor? Return the responses to the questions right here as a message. Round all final outputs to 2 decimal places.

Using the discount approval logs and the KPI chart, I'd like to get one number that tells me how risky our discounting behavior is right now. Looking at deals where the final approved discount exceeded policy, classify the severity using the chart, apply the risk sensitivity, and calculate the revenue exposure. Assume Policy Breach % is the difference between final approved discount and the policy threshold. Return to me a message with the Policy Breach Stress Index (rounded to 2 decimal places), which is the average revenue at risk per policy-breaching deal.

I would like to analyze the current proportion of Brightpath Churn and Annual Recurring Revenue. 1. Based on the ARR from the discount approval file and the Churned ARR from customer segmentation file, calculate the required reduction in $ in Churned ARR for every Pricing Tier whose current Churned ARR proportion exceeds 0.5% of its Overall ARR, so that the proportion for that tier is reduced to exactly 0.5%. 2. Calculate the number of additional deals (each valued at the average ARR per deal from discount approval report) required to meet a target of 0.5% Churned ARR as a percentage of total ARR. Print your response here. Round final dollar amounts to the nearest whole dollar. Round the number of deals up to the nearest whole number.

Calculate the price per share that a strategic buyer would need to offer for Golden Everest to consider an acquisition instead of a REIT conversion. Reply to me here with the minimum required share price. Round all final numbers to two decimal places. I want the 2027 expected share price discounted to 11/21/2025 (18 months) for “C-Corp Low”, “C-Corp Mid”, “C-Corp High”, “REIT Low”, “REIT Mid”, and “REIT High”. Assumptions: 1. It will take 18 months post REIT conversion for the stock to appreciate to fair value, assuming mid-2027 for this process to complete. 2. The discount rate is 4%. 3. Use the low, mid, and high multiples found in the model. 4. Assume the price needed to consider the acquisition is 10% above the valuation for the REIT using the mid multiple. 5. Reference 2025E EV/EBITDA multiples for C-Corp and REIT conversion, and pull 2027E EBITDA values from the model.

Model out the NPV of distributions shareholders would receive under REIT conversion. - There's the $1.2 billion E&P purge that gets taxed as ordinary income at 37% (E&P purge occurs at Year 0, annual distributions occur at end of Years 1–5). - There are ongoing REIT dividends in the $650-750mm range that qualify for the 20% Section 199A deduction. - Apply 199A only to annual REIT distributions; do not apply 199A to the E&P purge (tax purge at 37%). - Run sensitivities across 10%, and 12% discount rates over a 5-year horizon. Show discount rates vs distribution levels, populated with respective after-tax NPV per share. Then, show me the base case NPV as a percentage of both the strategic offer and current trading price. Round NPV per share to 2 decimal places. Round percentages to 1 decimal place. Create an xlsx that has all of your results.

Using the information in the REIT model, create a new sheet: - Re-run the Scenario3: REIT Conversion analysis in sheet "Valuation Summary" using FFO multiples in place of the current EBITDA multiples - Run a low case using Iron Mountain's FFO multiple - Run a High case using Digital Realty's FFO multiple Tell me this info for Low and High cases: - REIT Equity Value ($mm) - Implied REIT Price Per Share - Premium to Current Share price of $42.50 as of 11/21/25 Calculate Golden Everest's 2025E FFO metric by using Digital Realty's implied FFO value (from the information within the "Comparable Companies" tab ) as % of LQA Adjusted EBITDA for the period QE 3/31/2023 within the investor presentation Format all outputs as follows: - Round all dollar figures to 1 decimal place in millions ($m) and express in "$X.X" format - Round all percentages to 1 decimal place - Share price should be to two decimal places

For each year, calculate Levered FCF less Dividends Paid. Assuming a 9% discount rate, output the net present value (NPV) of Levered FCF less Dividends Paid over the projection period, rounded to a full million. Refer to REIT model and adjust Golden Everest Base Case Projections (C-Corp Status) as follows: - Hold Capex % of Revenue constant at 22% over the projection period - Assume Dividend per Share is fixed at 1.60 in 2025E, increasing 0.40 per year over the projection period. Print your answer to me here via a short message.

Using the REIT model, assess the downside REIT scenario for Golden Everest if data center REIT multiples compress 30% during a longer than expected conversion period of 12 months. Reply to me in here with a message which states the expected price in 12 months of Golden Everest in this downside scenario and the expected total return of the stock over that period. Round all numbers to 2 decimal points. Assumptions: 1. Stock price will be calculated off of 2026 expected earnings 2. Dividends are not re-invested 3. Only half of the REIT premium (post-compression) vs C-Corps will be realized over the 12 months 4. No change in net debt

Make adjustments to the Year 5 growth rate to reach the following Year 1 - Year 5 CAGR for Total Revenue: 22%. Use the LBO model to complete the analysis, but just reply right here. Round value to one decimal place. Make these changes: 1. Year 1 revenue growth rate increases by 188 bps 2. Year 5 revenue growth rate increase by 1/8 the current % premium

Please assess the impact of reducing the entry premium by 5% and illustrate the potential impact on the deal return. Use the LBO model. 1. Reduce the deal premium by 5%, from 35% to 30%. 2. Reduce the Exit Multiple from 35.0x to 34.0x. 3. Ensure all interest expense calculations are based on the average of the beginning and ending debt balance in the period. Report just the MOIC and IRR %, return it back here. All percentages and multiples must be rounded to two decimal places.

Print out here the updated IRR and MOIC, rounded to two decimal places. Use the precedent transactions document and LBO model to complete the analysis. Assumptions: 1. Adjust the LBO model to have the premium % equal to Splunk Inc's revenue growth rate in the precedent transactions document 2. Adjust year 4 revenue growth in the LBO to New Relic, Inc's revenue growth rate in the precedent transactions document

Use the LBO model. I want some new analyses: - Decrease the “Premium” from 35.0% to 25.0% on the "LBO" tab - Decrease the “Adj. EBITDA Multiple” from 40.0x to 25.0x on the "LBO" tab - Update revenue growth constant at 15.0% per year from Year 2 through Year 5. Write out to me here: 1. Sponsor Equity Value in Year 5. 2. IRR in Year 5. Round it to the nearest million (e.g., $1,000). Report the IRR as % rounded to one decimal place.

Using the State of Fashion Beauty report for 2024 sales and sub-category shares, alongside the attached data for Mass Market vs. Premium share by sub-category, calculate the difference (in $M) between the North American Mass Market and Premium segments for Skincare and Fragrance. Assume North American breakdowns by sub-category and segment match those of the global benchmarks. Report values as positive if Mass Market is larger and negative if Premium is larger. Using the data from the internal financials spreadsheet, determine Lumea's North American market share of the Premium segment of each sub-category (Skincare and Fragrance). Assume North American revenue percentages are uniform across all segments, all Lumea sales are Premium, and Lumea's Skin and Body units fall under Skincare. Round currency outputs to the nearest $0.1M and round percentage outputs to the nearest 0.1%. Provide your findings to me here in a reply.

Can you take a look at Lumea's 2025 financial report and the global beauty market analysis and help me double check their margin target? Specifically: a) If Lumea were to reach the midpoint of the premium-player operating margin range (instead of their 2030 target), what would their operating profit be in 2030? b) What's the delta with Lumea's 2030 operating profit target? c) How big is that delta as a % of Lumea's 2030 revenue target? Provide all your answers directly to me here as a message. Round the dollars to the nearest million and % to one decimal.

Use Planet Fitness' latest financial model that Advent updated based on their specifications and assess Advent’s “ability to pay” to reach 25% IRR after 5 years if there are net revenue synergies between Planet Fitness and a portfolio company that Advent already holds. Assume exit multiple is 18x and estimated revenue synergies are as follows: $10 million per quarter (Q1-Q4 2026); $50 million per quarter (Q1-Q4 2027 and beyond). Assume no incremental costs associated with the net revenue synergies. Reply to me with a message outlining the implied premium paid to reach 25% IRR, assuming the revenue synergies above.

Planet Fitness is looking to divest its entire 281 stores, which it owns as of September 30, 2025, to a franchise owner. Round all results to two decimal places and present it in $mm. Using the LBO model, perform a DCF analysis for the company as per the base case scenario for the projected cash flows for the 281 stores, and assume the following: 1) Assume that the average revenue per store increases by 5% YoY for every quarter from Q4 2025 through the end of 2030 2) Assume EBITDA margin for the business remains at 39% every quarter from Q4 2025 through the end of 2030 2) Assume that the effective tax rate is 20% 3) Assume that the depreciation rate is 5% of the revenue 4) Assume that maintenance capex is 2% of sales and there is no growth capex 5) Assume a discount rate of 12% and terminal growth rate of 2% 6) Do the enterprise valuation as of December 31, 2025 Print here the FCFF for 2026 to 2030. Also give the Enterprise Value of the corporate-owned store business

Conduct a 5-year IRR sensitivity analysis using Planet Fitness' latest financial model that Advent updated based on their specifications (v7). Assess the IRR impact to Advent if the terms of the debt raised changed while keeping 10% offer price premium and 18x exit multiple. Calculate the 5-year IRR when Debt Raised at Close at 6.5x, 7.0x EBITDA and interest rate at 6.5% and 7%. You can use a "Copy of LBO" tab. Round all calculated numbers to one decimal place. Reply back to me here with the information I've asked for.

Use the LBO analysis, update it to assume that Planet Fitness stock option tranches outstanding. I want to see the Year 5 IRR, flexing premium paid and exit multiple. # Assumptions -All options are vested or will vest in the event of a transaction -3 tranches of stock options outstanding: *5.0 million shares at a strike of $105.00/share *4.0 million shares at a strike of $110.00/share *5.0 million shares at a strike of $116.00/share # Output In the LBO analysis file create a new sensitivity table, with the Entry Premium % of 5% and 15%. Also show the Exit Multiple of 16x, 18x and 20x. Round final monetary values to nearest million. Round all other values to 1 decimal point.

Calculate the sponsor equity value and IRR for FY2030, then report the sponsor equity value in US dollars, rounded to the nearest million, and report the IRR as a percentage rounded to one decimal place. Use the LBO model. Reply straight back to me please, with everything I requested. Use these specs: - Increase the “Secured term loan - USD tranche” leverage from 6.0x to 7.5x LTM EBITDA and decrease the yield from 7.50% to 6.50%. - Hold revenue growth constant at 12.0% per year from FY2026 to FY2030. - Decrease the % Premium to 5.0% from 10.0%.

Using the LBO analysis, conduct a Purchase Price Allocation to show the amount of pro-forma goodwill created from this transaction. Also show the allocable purchase premium. Round all monetary values to the nearest million. Write back the results as a message to me in here. # Assumptions - Balance sheet figures sourced from the "Balance Sheet" tab, using FY25E data (as of Q425) - Intangible Assets Write Up: Intangible asset allocation %: 10.0%. Useful life assumption: 15 years - PP&E Write Up: PP&E write up %: 10.0%. Useful life assumption: 8 years - Tax rate of 25%

Use Planet Fitness' latest financial model, and conduct an ability to pay analysis around Advent's target IRR of 25%. Create a new xlsx sheet, then round all calculated values to two decimal places for: the implied premium paid when target IRRs are 20.0%, 22.5%, 25.0%. Exit multiples are 18x and 20x.

From the LBO, assume a 15% premium is offered to CNS holders and max transaction leverage of Term loan B is $1,040. What is the revised IRR and MoM for 2029E, rounded to one decimal place? Reply here.

Provide the mean implied equity value for CNS from the Comparables and Precedents using 2025E EBITDA, as well as the implied equity value from the DCF and LBO using the base DCF and assumed offer price. Provide the results of all four methods and the mean in $ million, to one decimal place. Give it as a message right here.

Your task is to evaluate the impact of financing constraints on Project Vanguard's take-private economics and develop a revised LBO case reflecting a capped leverage scenario using the LBO model. • Term Loan B (TLB): cap maximum proceeds at $1,250 MM • Adjust Sponsor Equity so that Total Sources = Total Uses, maintaining a constant enterprise value (EV) at entry (excluding fees and cash to balance sheet). • Exit Multiple: assume 2030E Exit Multiple of 18.5x In the existing LBO model, I want you to compute the Implied Adj. EBITDA Entry Multiple (2024A). Label this calculation as: “Implied Adj. EBITDA Entry Multiple (2024A)”. Also, create a 2x2 sensitivity tables for Sponsor IRR (%). Set rows as: Premium to Current (15.0%, 25.0%) and columns as: Exit Multiple (17.5x, 18.5x). Populate the tables with recalculated IRR values based on the revised capital structure reflecting the Term Loan B cap. Round the final results to one decimal place and keep the same formatting as the original sensitivity table.

Please calculate the total value of a MFC privatization by the provincial government at a bid value of 11x LTM EBITDA, which composes of both the (a) upfront proceeds from the sale and (b) value of the tax stream, assuming the following using the MFC model: * The province receives 1/3 share of the corporate tax (the other 2/3 going to the federal government) * Given its "super-priority", the discount rate on the tax stream is 4% * The terminal growth rate of the tax stream is expected to be the 2032 revenue growth rate of MFC Please provide your response to me here, in millions of dollars that are rounded to the nearest million.

Calculate a normalized market capitalization for AES using data from the comps file and the following approach: - Calculate the volume‑weighted average price (VWAP) for AES Corporation over the 250 trading days to 20 Nov 2025, in two steps: Step 1: For each trading day, compute the daily dollar value by multiplying the average of that day’s high, low, and close prices by the total volume traded that day, then sum these daily dollar values over the full 250‑day period. Step 2: Divide this 250‑day cumulative dollar value by the cumulative trading volume over the same 250‑day period to arrive at the 250‑day VWAP. - Determine the percentage share price increase (premium) by comparing the 20 Nov share price to the 250‑day VWAP. - Normalize AES Corporation’s market capitalization by removing the premium of the most recent share price over the 250‑day VWAP, so that the resulting normalized market capitalization reflects the VWAP rather than the latest trading price. Return only the final result to me right here as a short message. Give it in billions of Canadian dollars (C$) and rounded to one decimal place.

Using the DCF model, update the equity risk premium to be the risk-free rate plus 150 basis points and the cost of debt to be the risk-free rate plus 300 basis points Output the following rounded to two decimal places: - Implied DCF share price with a terminal growth rate of 1.25% and 5-year risk free rate of 12/12/2025 - Implied DCF share price with a terminal growth rate of 1.25% and 7-year risk free rate of 12/12/2025 - Implied DCF share price with a terminal growth rate of 1.75% and 5-year risk free rate of 12/12/2025 - Implied DCF share price with a terminal growth rate of 1.75% and 7-year risk free rate of 12/12/2025

Use the valuation model, updating the 'Per Share' and 'Premium' values for the low, mid, and high cases to reflect Blackstone’s acquisition of Company X and the assumptions below. Reply back to me with the per share data in € and the Premium. Round percentages to 1 decimal place. Assumptions to follow - Blackstone acquired Company X in 2020 at an EV of €1000M - Company X revenue was €100M - Company X EBITDA was €50M - Blackstone acquired Company X at a 45% premium - The Stevanato - SVM Automatik transaction is an outlier and should be excluded from the analysis - The Mid EV/EBITDA multiple is the average of the High and Low multiples - Gerresheimer recently completed a capital raise that is not reflected in the base case, issuing10 million shares at €30.00 per share - Gerresheimer used €200M of the proceeds raised to acquire 49% of Company Y that has €50M in EBITDA

Assume that 10% of Aptar's Asian pharma revenue will shift entirely into European pharma revenue. Retroactively apply this to 2024 financials. Refer to the 2024 ATR report. Return a short message with the values for Asia Pharma and Europe Pharma for their corresponding revenue under this set of assumptions. Round dollar amounts to the nearest thousand.

From Becton Dickinson's FY2025 Annual Report assume the FDA finds that one violation regarding the Alaris SE infusion pumps, and decides the company is in violation, and enforces the consent decree on Alaris SE infusion pumps from November 29, 2024, to November 28, 2025, inclusive. Compute the average dollar burden of the penalty on BDX average shareholder. Output the result in USD as a reply to me here, rounded to 4 decimal places. Assume a 30-day month and a 360-day year.

Please access the 2024 Huhtamaki Annual Report and calculate the Net Sales per employee at end of period for 2023 and 2024. Reply to me here with the the Euros per Employee, rounded to the nearest full Euro amount.

The current standalone DCF valuation does not include synergies. In the valuation model, re-run the analysis to include synergies, integration, and transaction costs. In the accretion dilution model project, the "Synergies" and "ProForma_Combined" tabs contain these assumptions. 1. Update the vauation model "Project_Rheingold_Valuation_Model(final)" 2. Implement One-Time Integration Costs (After-Tax), Transaction Costs (After-Tax), and EBITDA Synergy (pre-tax) into the DCF analysis, maintaining all existing DCF assumptions. 3. Report back for me: "Sum of PV of FCF (2026-2030)", "PV of Terminal Value", "Enterprise Value", "Implied EV/EBITDA(2025E)", "Implied EV/Revenue(2025E)". 4. Round all final monetary values (millions) and multiples to one decimal place.

If the value of ATRs holdings of Goldrain and YAT appreciated by 5% and 10% respectively, from the end of 2024, while all other equity investments remained constant, what would the new total value of ATR equity investments be? You should respond here with a single dollar amount. Round to the nearest thousand and return the complete dollar amount. Reference the 2024 ATR report for all required information. Write out right here for me what I need.

Using the 2024 ATR annual report, analyze the results of a 15% tariff on Aptar Group’s FY2024 net income. Assume the 15% applies only to Cost of Sales, exclusive of depreciation and amortization. Round all values to the nearest thousand. Use a 20.35% tax rate. Output just the pro-forma net income as a reply here.

In The Aptar Group's 2024 annual report, extract global revenue for the Pharma segment in 2023 and 2024. Compute the aggregate dollar change in thousands of USD adjusted for 7.1% 2024 global inflation and express the result in USD, rounded to the nearest thousand. Print back to me what you find please.

Using the 2024 ATR annual report, reply to me with the absolute performance difference between ATR shares and the Peer Group in 2024 as a percentage (round this to two decimal places).

You have access to the accretion dilution model. Create a new sheet and tell me the Proforma Interest Coverage for 2027 and 2028. In doing so, assume: - Aptar's Interest expense as a percentage of sales in sheet "Aptar_Historicals" is now 2% for the projection period (2025E - 2030E) - Aptar's Total OPEX as a percentage of sales in sheet "Aptar_Historicals" is now 25% for the projection period (2025E - 2030E) - Aptar's Tax Rate as a percentage of sales in sheet "Aptar_Historicals" is now 35% for the projection period (2025E - 2030E) - Interest on Existing debt remains unchanged. - Cost synergies target in sheet "Synergies" is 35% - Synergies in sheet "Synergies" will be 50% realized in 2025, 2026 and 2027 and 100% in 2028 and after - Cost to achieve synergies in sheet "Synergies" will be 0% Perform the calculations in Euros in thousands and round to one decimal place.

Calculate the incremental Enterprise Value the Gerresheimer acquisition will add to the Aptar Group. Only reference the board presentation. Assume multiples for The Aptar Group remain constant and reference the acquisition multiple of 4.5x for Gerresheimer to arrive at the acquisition price. Use 2025E EBITDA. Do not incorporate synergies. Express your answer as a message right here. Give numbers in USD million, rounded to one decimal point.

Determine the effective interest rate of The Aptar Group acquiring Gerresheimer at a 35% premium. Then compare that effective interest rate to the effective interest rate of The Aptar Group as a standalone without acquisition. Use the board presentation to calculate the effective interest rates. Round the interest rates to one decimal point. Assume a 25% corporate tax rate. Create a New Sheet file with the Effective Interest Rate for Aptar Standalone and Aptar with Acquisition.

ATR is expecting to write down the goodwill related to Pharma to zero following the merger with GXI. Referring to the 2024 ATR 10K calculate the new total ending Goodwill under this write down scenario and output the number. Round it to the nearest thousand dollars. Tell me the information that I want in here.

Create a new Spreadsheet for me. Please compute a new Adjusted EBITDA value for the following companies: West Pharmaceutical, Stevanato Group, Schlott Pharma, Berry Global, Aptar Group using the board presentation, by taking the peer group median EBITDA margin and the corresponding revenue values. Multiply the Adjusted EBITDA values by the peer group median EBITDA multiple to derive a new Enterprise Value for each company. Report back the values. Display all margins and multiples to one decimal place and revenues, Adjusted EBITDA, and EVs to the nearest whole number, expressed in $mm.

Calculate the 2030E discounted EV/Revenue multiples for West Pharmaceutical, Stevanato Group, Schott Pharma, and Aptar Group. Reference the valuation model on the "Trading Comps" tab. Note that the financial and valuation metrics reflect 2025E assumptions. For each company, assume that the long-term revenue growth rate starting in 2026E is equal to its FY23 - FY24 YOY net sales growth rate, and the discount rates are as follows: West Pharmaceutical -> Reference WST 2024 10K for revenue growth -> Discount Rate: 9.4% Stevanato Group -> Reference Stevanto 2024 20-F for revenue growth -> Discount Rate: 8.8% Schott Pharma -> Reference Schott 2024 annual report for revenue growth -> Discount Rate: 10.0% Aptar Group -> Reference ATR 2024 10K for revenue growth -> Discount Rate: 7.4% Round the final output to one decimal and express it as a multiple. Print out what you find for me in here.

Reference 2024 ATR annual report to calculate Aptar Group's cash conversion cycle for FY2024, using FY2024 ending balance only. Output the cash conversion cycle in days, rounded to the nearest whole number. Respond with the information right here.

Calculate and report the adjusted diluted EPS growth for FY2023 to FY2024 for Amcor and unadjusted diluted EPS growth for The Aptar Group, rounded to the nearest whole percentage. Use the Amcor and ATR 2024 annual reports. Reply to me with the correct values here.

Our client, SLL, offers discounts to senior clients who opt into receiving texts about new products and services when they apply for loans from SLL. A prospective customer, Angie, agreed to receive marketing texts for a 10% discount on a mortgage for her crafts store and verbally told her loan officer that he may communicate updates and concessions from SLL via text. Angie is now filing a complaint against SLL for causing her to be “inundated with texts.” She claims that the discount is coercive for elders. Can you analyze the merits of Angie's complaint? Please reply to me with a short summary of your conclusions and a brief explanation in reference to the attached memo, laws, and SLL's policies (assume they were followed) in a few paragraphs.

Using the McKinsey wellness report and our buyer profile analysis, recalculate Supplement pricing with two factors only: Vitamins and Supplements preference and increased spending. Apply as multipliers to base the current recommended base premium %. Show the new recommended price The final answer should be formatted to US$, rounded to 2 decimal points. Write it out here.

Using the consumer perception data and pricing details from the buyer profile, determine how many survey respondents in each market have never heard of PureLife and are willing to pay more than a 30% premium above average price for trusted brands. Give it as both a count and as a percentage by market. In which of the three surveyed markets would these customers be willing to pay more than $20 for a trusted brand? State both the market(s) and the price(s). All intermediate and final calculations should be rounded to three decimal places. Return all of the outputs to me as a message in here.

Evaluate the sensitivity of EPS impact to synergies and cost of new debt for the acquisition of SOLV by MMM using the accretion dilution model. Create a new tab in the file, with a table to show EPS impact (accretion or dilution). - Show synergies in increments of $300 million (300m, 600m). - Show cost of new debt in increments of 5ppts (15%, 20%). - Show the price premium per share at different synergy levels. - Assume the price premium per share is 25% for no synergies and increases by 2.5ppt every $100 million in synergies. - Two dec points only.

Under Scenario 1 in the Accretion / Dilution Model, 3M will use 50% debt / 50% equity. $250 million in pre-synergies were identified. Use the following assumptions in the Assumptions S1 tab of the Accretion / Dilution model: - Pre-Tax Synergies: $250mm - Control Premium: 25% - % Stock: 50% - % Debt: 50% - Interest Rate on New Debt: 8% - Fees: 1.5% of Updated Take-Private Enterprise Value - Solventum Share Price: Use the Solventum VWAP for the 75 trading days up to November 19, 2025. To calculate the price for each trading day in VWAP, use the formula (High + Low + Close) / 3 We need the Revised Accretion / Dilution percentage for 3M. Round percentages to 2 decimals points. Write back to me with your response now.

Perform a value-creation analysis based on scenario 1 using the accretion dilution model to assess whether Scenario 1 creates or destroys value for 3M Shareholders. Assumptions: 1. 3M Levered Beta is 1.15 2. Risk free rate is 4.00% 3. Equity risk premium is 5.50% 4. Calculate cost of equity using CAPM: Risk-free rate + Beta*Equity Risk Premium 5. Implied Return = SOLV Net Income/Purchase Price Paid 6. Assume Spread is calculated by Implied Return - WACC 7. For PF WACC, use 3M's existing cost of debt from Scenario 1 and assume the incremental acquisition debt carries a 10.00% interest rate (consistent with Scenario 1 assumptions). Print the output here. Format all final percentages to two decimal places.

Solventum (SOLV) announced a $2.0 billion strategic expansion funded with 70% debt and 30% equity, which caused its share price to increase by 5% relative to the closing price on 11/18/2025. Using the most recent accretion/dilution model rerun scenario 1, assuming the updated SOLV share price. Determine the revised premium 3M would pay under the updated assumptions to keep EPS accretion flat relative to the level from the original 30% premium case. Write back to me with what I requested. In the output, round the percentage to two decimal places.

Calculate the accretion / dilution of both BBDC and TVPG shareholders, sensitized for different Cash consideration and Bid Premium. Edit the existing merger model and add two sensitivity analyses: one showing BBDC accretion/dilution and one showing TVPG accretion/dilution, each sensitized to bid premium (10% and 20%) and cash consideration (10% and 15%). Assume an increase of EBIT Synergies by 480bps and a 210bps decrease in post-deal bidder share price downside. All output values should be in %, rounded to 2 decimal places.

Use the BBDC valuation model as a template and a prepare a full valuation of SLR INVESTMENT CORP. (SLRC) as of FY 2024. - Use the median of peer trading multiples - Retrieve the SLRC’s required data from the attached SLRC 10K files. - Use the share price as of December 31, 2024 ($16.16) for SLRC's actual equity value. Calculate SLRC’s Implied Equity Value according to the following methods: - P / NAV, P / E, P / Sales, and NAV / Share I want you to compute the Relative Premium / (Discount) of SLRC’s actual equity value. Then, determine the lowest and highest Implied Equity Value from all the valuation methods. Round to the nearest unit for the lowest and highest Implied Equity Value in thousands dollars. Round to 2 decimal places for the Relative Premium / (Discount) results in %. Print the correct information back to me here.

Based on the attached table, with the asking price for each company, which competitors would have a higher 2024 ARR multiple than CompliSure even if their SMB customer count declined by 75%? State the updated 2024 revenue ARR multiple for each of those companies. Use the KPI dashboard, expanded financial dataset, and competitors client share files along with the attached files for this analysis. You can write your response back to me in here.

Create a new slide pptx, summarizing the comparable SaaS deals' target company name, purchase price, ARR, and ARR multiple. Include all targets for which we have an individual case study and use only publicly disclosed data. Round multiples to one decimal point and, for financial values, provide numbers in millions rounded to the nearest million or, if above 1 billion, in billions with one decimal place. Get insights from the comparable SaaS deals, the internal memo about valuation ranges and negotiation levers, and the case studies about Beacon, Stuzo, TASK, Claap and Statsig.

I feel good about our current assessment of the valuation, but I’d like to do some forward-looking assessments. Can you use the historical Sector Median PE volatility data to determine which of the currently undervalued stocks are at the highest risk of becoming overvalued. Give me the company name, ticker symbol, and the probability percentage. Just to reiterate, a premium of 25% or more over the Sector Median PE is considered overvalued. Anything else is undervalued. Use 28.5 as the current Sector Median PE. I think it’s fair to assume the same PE volatility distribution will continue. Round final percentage to two decimal places. Reply back to me with your answer.